Comparative Pharmacology
Head-to-head clinical analysis: TAVIST versus XYZAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAVIST versus XYZAL.
TAVIST vs XYZAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; selective inverse agonist at histamine H1 receptors, blocking histamine-mediated allergic and inflammatory responses.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
1.34 mg orally twice daily; maximum 8.04 mg/day.
5 mg orally once daily in the evening.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in renal/hepatic impairment.
Terminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Renal excretion of metabolites (approx. 60%) and unchanged drug (<5%); biliary/fecal elimination accounts for about 40%.
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Category C
Category C
Antihistamine
Antihistamine